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Abstract
Background: Homozygous familial hypercholesterolaemia (HoFH) is characterized by a markedly increased risk of
premature cardiovascular (CV) events and cardiac death. Lomitapide reduces low-density lipoprotein cholesterol
(LDL-C) levels; however, the probable impact on LDL-C goals and CV events is unknown.
Methods: We used data collected in the first 26 weeks of the lomitapide pivotal phase 3 study (NCT00730236) to
evaluate achievement of European Atherosclerosis Society (EAS) LDL-C targets. We used publicly available data
reporting major adverse CV events (MACE) rates from other cohorts of HoFH patients to compare event rates for an
equivalent number of patient years of exposure (98) in the lomitapide extension trial (NCT00943306).
Results: Twenty-nine patients were included in the phase 3 study. During the first 26 weeks, 15 (51%) and eight (28%)
reached LDL-C targets of 100 mg/dL and 70 mg/dL, respectively, at least once. Fourteen (74%) and 11 (58%) of the 19
patients who remained in the extension study after week 126 reached LDL-C targets of 100 mg/dL and 70 mg/dL at
least once during the entire study period. Only two MACE were reported in the lomitapide trials (one cardiac death and
one coronary artery bypass graft (CABG)) – equivalent to 1.7 events per 1000 patient months of treatment. MACE rates
were 21.7, 9.5 and 1.8 per 1000 patient-months respectively in cohorts of HoFH patients pre- and post-mipomersen, and
receiving evolocumab. On treatment LDL-C levels were 166, 331 and 286 mg/dL for lomitapide, mipomersen and
evolocumab, respectively.
Conclusions: Approximately three quarters and half of patients who took lomitapide for at least 2 years reached LDL-C
goals of 100 mg/dL and 70 mg/dL, respectively. There were fewer major CV events per 1000 patient months of treatment
in patients taking lomitapide, mipomersen or evolocumab than reported in the mipomersen cohort prior to starting
mipomersen. These results support the hypothesis that novel lipid-lowering therapies may reduce CV events in HoFH
patients by lowering LDL-C further.
Trial registration: NCT00730236 (registered 8 Aug 2008) and NCT00943306 (registered 22 July 2009).
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Background
Homozygous familial hypercholesterolaemia (HoFH) is a
rare genetic condition characterised by markedly ele-
vated low-density lipoprotein-cholesterol (LDL-C) levels,
inadequate response to conventional drug therapy and
premature-onset cardiovascular disease (CVD) [1].
HoFH is most commonly caused by the occurrence of
two LDL receptor (LDLR) gene mutations, but can also
be caused by mutations in other genes that directly or
indirectly act on the LDL/LDL-receptor pathway, includ-
ing the genes encoding apolipoprotein B (apoB; APOB),
proprotein convertase subtilisin/kexin type 9 (PCSK9),
and LDL-receptor adaptor protein 1 (LDLRAP1) [1]. If
untreated, patients with HoFH often die from premature
CVD in adolescence or early adulthood [2].
The aim of therapy in HoFH is to aggressively reduce
LDL-C levels to prevent or delay the onset of premature
CV events. The European Atherosclerosis Society (EAS)
has suggested that patients with HoFH should be treated
to the same LDL-C targets set for other patients requiring
lipid-lowering therapy, namely < 100 mg/dL (2.6 mmol/L)
for primary prevention, and < 70 mg/dL (1.8 mmol/L) in
the presence of clinical atherosclerotic CVD [1]. These
targets are not achievable in the majority of HoFH pa-
tients with currently available standard therapies that re-
quire functioning LDL-receptors, such as statins,
ezetimibe [3] and inhibitors of PCSK9 [4].
Lipid apheresis does not require functional LDLR and
can reduce LDL-C further but is invasive and not uni-
versally available. Even with the use of apheresis, targets
are often not achieved [5].
Lomitapide is an oral microsomal triglyceride transfer pro-
tein inhibitor that reduces the assembly of apoB-containing
lipoproteins in the intestine and liver, and therefore does not
require functioning LDL-receptors to lower LDL-C levels
[6]. Lomitapide was approved as adjunctive therapy in adult
patients with HoFH following a small open-label single-arm
Phase 3 study. In this study, lomitapide resulted in mean
LDL-C reductions of 50.7% (Week 26; safety population;
mixed-model repeated measures analysis [7]).
We hypothesise that such large decreases in LDL-C,
and in particular the attainment of the EAS recom-
mended LDL-C target levels, may result in a lowered
risk of CV events. A paper was recently published mod-
elling the potential improvement in survival and the
delay to first major adverse CV event (MACE) in treat-
ing patients with HoFH [8]. Formal CV outcome studies
to test this hypothesised benefit are not feasible in HoFH
due to the relatively small number of affected patients,
and ethical concerns about withholding potentially ef-
fective therapy from patients with a very severe disorder
for prolonged periods of time in a double blind rando-
mised placebo-controlled trial. Therefore, this analysis
was conducted to examine the actual benefit achieved in
treating patients with HoFH. The objectives of this post
hoc, retrospective analysis are to determine the number
of HoFH patients receiving lomitapide who reach EAS
targets within 6 months, and to compare cardiovascular
event rates in patients receiving lomitapide with pub-
lished data.
Methods
Study population
We analysed data from two lomitapide studies: a
single-arm, open label, Phase 3 clinical trial of lomitapide
in adult patients with HoFH (NCT00730236; the ‘pivotal
trial’) and its single-arm extension study (NCT00943306;
the ‘extension trial’). Both trials received local institutional
review board and regulatory approval. All patients pro-
vided written informed consent before participating in the
trials, and institutional review boards at each site provided
approval of the protocol. Patients enrolled in the pivotal
study were required to maintain current lipid-lowering
therapy, including apheresis, from 6 weeks before baseline
through to at least Week 26. Lomitapide dose was esca-
lated according to safety and tolerability from 5 mg to a
maximum of 60 mg/day. The primary endpoint was mean
percent change in levels of LDL-C from baseline to Week
26, after which patients remained on lomitapide through
to Week 78 for safety assessment. Percent change in
LDL-C from baseline was assessed with a mixed linear
model [7].
Eligible HoFH patients completing the 78-week Phase
3 pivotal trial were encouraged to enrol into a
single-arm extension study where lomitapide was admin-
istered daily at the prior maximum tolerated dose (5–
60 mg/day) until lomitapide was commercially available
in the patient’s country. Patients living in countries
where lomitapide was not commercialised were switched
to compassionate use [6]. In the safety phase of the piv-
otal trial (Weeks 26–78) and in the extension trial,
changes in the background lipid-lowering therapies were
permitted based on physician discretion. Changes to
apheresis therapy were only permitted if the patient
achieved an LDL-C level ≤ 100 mg/dL [6].
Cardiovascular event rate comparison
A recent publication by Duell et al. provided a basis from
which to calculate cardiovascular event rates in a cohort
of HoFH patients receiving conventional lipid-lowering
therapy [9]. The authors utilized data from three clinical
trials of FH patients receiving mipomersen, plus an
open-label study extension phase [9]. Patients who re-
ceived at least 12 months of mipomersen were included in
the analysis. Of the 233 patients analyzed by Duell and
colleagues, 51 had HoFH, of whom 23 received at least
12 months of mipomersen therapy [9]. Data from these 23
patients prior to and after starting mipomersen was used
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for comparative purposes. We also calculated annualised
and per 1000 months MACE rates in a HoFH cohort
treated with evolocumab based on a recent publication by
Raal et al. [10].
For our analysis, we defined MACE as CV death,
non-fatal myocardial infarction, coronary revasculariza-
tion, unstable angina and/or ischemic stroke, to allow for
comparisons across trials. We collected MACE data from
adverse event reporting during the lomitapide studies, as
MACE was not a pre-specified outcome in these studies,
and no formal adjudication of MACE during either lomi-
tapide study was made. In the mipomersen studies MACE
prevalence pre-treatment was obtained from medical his-
tory and case report forms, while MACE incidence was
formally adjudicated once patients had commenced treat-
ment with mipomersen [9]. MACE was formally adjudi-
cated in the evolocumab study [10, 11].
Results
LDL-C levels in the phase 3 trial and extension trial
The Phase 3 pivotal study enrolled 29 adult men and
women with HoFH from 11 centres in four countries
(USA, Canada, South Africa, and Italy). Twenty-three of
29 enrolled patients completed both the efficacy phase
(26 weeks) and the safety phase (26–78 weeks) [7]. The
patients entering the pivotal study were receiving stand-
ard of care for HoFH with 93% of patients receiving sta-
tins, 76% of patients received ezetimibe while 62% of
patients were treated with apheresis. Despite this aggres-
sive therapy, the mean LDL-C at baseline was 336 ±
114 mg/dL (8.70 ± 2.95 mmol/L) [7]. Study visits and
LDL-C measurements were always scheduled to take
place just prior to the next treatment session in patients
receiving apheresis.
Following treatment with lomitapide (median dose
40 mg), LDL-C was reduced by mean of 50.7% (Week
26; safety population; mixed model repeated measures
analysis; 40.1% for last observation carried forward ana-
lysis; Table 1) [7].
Nineteen of 23 patients who completed the pivotal study
entered the long-term extension trial (9/19 apheresis) with
16 patients completing all end of study assessments.
Lomitapide LDL-C-lowering efficacy was maintained
during the extension study and was − 45.5% at Week 126
(Table 1) [6].
In the original cohort (n = 29), just over half of pa-
tients reached a target LDL-C level < 100 mg/dL at
least once by Week 26, and most who remained in
the study reached target at least once by Week 78,
increasing to 74% by Week 256 (Table 2). The EAS
target for patients with clinical atherosclerosis is an
LDL-C level of 70 mg/dL or less. Since most of the
patients in the studies had CVD (27/29 in the Phase
3 and 17/19 in the extension study), this is the most
relevant target for the present analysis. Twenty-eight
percent (8/29) of patients reached this stringent target
of < 70 mg/dL at least once by Week 26, increasing
to 39% of those who remained in the study by Week
78. For the population in the extension trial, 42% had
reached the < 70 mg/dL target at least once by Week
126. A further three patients (58%) had reached this
target at least once by the end of the extension study,
Week 256 (Table 2). When target achievement was
assessed over time in the two studies combined, five
of the 19 subjects never achieved target, and 14
achieved the LDL-C < 100 mg/dL target once. Of
these, 13 reached this target at least on one further
occasion during the study. The median number of
visits at which LDL-C < 100 mg/dL was achieved dur-
ing the entire study was 6.0 (range 1–20). The me-
dian number of visits at which LDL-C < 70 mg/dL
was reached during the entire study was 3.0 (range 1–
16). Patients participated in the long-term extension study
for variable periods of time, as the extension study usually
terminated when lomitapide became commercially avail-
able in the participant’s country. The median number of
on-treatment visits was 25 (range 17–28).
As physicians were permitted to amend background
lipid-lowering therapies including apheresis (upon
achievement of LDL-C < 100 mg/dL) after Week 26, this
analysis does not suggest that patients who reached tar-
get at least once did so continuously post adjustment of
background therapy. Variable compliance or lomitapide
dose adjustments in response to treatment-related ad-
verse effects could also compromise maintenance of
LDL-C at target.
Table 1 Mean percent change from baseline in LDL-C levels in pivotal and extension studies
Time point n Observed value, mg/dL (SD) Observed change, mg/dL (SD) Percent change, % (SD)
Baseline 19 342.8 (125.87) NA NA
Week 26 19 158.4 (89.65) − 184.4 (119.15) −50.7 (26.77)
Week 78 19 161.2 (59.55) − 181.7 (110.76) − 49.0 (19.46)
Week 126 17 188.8 (120.30) −166.8 (100.28) −45.5 (31.35)
Week 256 14 143.4 (83.18) − 224.9 (108.97) −60.1 (18.51)
LDL-C Low-density lipoprotein cholesterol. Values represent percent change in LDL-C levels ± SD from baseline for patients entering the long-term extension
study [6]. Background lipid-lowering therapies were fixed until Week 26. Week 78 marks the beginning of the extension phase
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Cardiovascular event rate comparison
Only two MACE were reported in the lomitapide tri-
als, both occurring in the long-term extension study
(one sudden cardiac death and one coronary artery
bypass graft (CABG)). This is equivalent to 1.7
events per 1000 patient months of treatment, or a
2% annualized event rate. Duell et al. [9] recorded 12
MACE in the 23 HoFH patients in the 2 years prior
to receiving mipomersen, which equates to 21.7
MACE/1000 months of observation, or a 26% annu-
alized event rate. The MACE rate in the mipomersen
cohort decreased to 9.5/ 1000 months following ini-
tiation of mipomersen. The MACE rate in the
HoFH cohort treated with evolocumab was 1.8/
1000 months.
Table 3 shows further details of the MACE rates in the
cohorts studied.
Adverse events on lomitapide
The present analysis does not include any additional ad-
verse event data beyond those reported for the pivotal
Phase 3 trial and the extension study of lomitapide. The
Phase 3 study reported gastrointestinal symptoms as the
most common adverse event. Experience to date shows
that the gastrointestinal symptoms are mostly manageable
with dose reductions or temporary treatment interrup-
tions. Four patients experienced elevated aminotransami-
nase levels of more than five times the upper limit of
normal. These resolved after dose reduction or temporary
interruption of lomitapide, and no patient permanently
discontinued treatment due to liver abnormalities [6]. In
common with mipomersen, lomitapide use is associated
with increased hepatic fat (hepatic steatosis), with large in-
terindividual variability in the magnitude of increase. The
long-term impact of hepatic steatosis associated with
lomitapide use is currently unknown. Both the Food and
Drug Administration (FDA) and European Medicines
Agency (EMA) require lomitapide prescribers to regularly
evaluate patients for hepatotoxicity and other adverse ef-
fects under risk management programs. Although, adverse
events (AEs) may limit the use of lomitapide in some pa-
tients no terminations due to drug related AEs were re-
ported for the remainder of the extended follow-up period
after the six terminations due to non-compliance/gastro-
intestinal (GI) AEs that were observed in the efficacy
phase of the trial [5].
Discussion
Lomitapide, in combination with other lipid-lowering
therapies is an effective treatment for the reduction of
LDL-C levels in adult patients with HoFH, allowing
Table 2 Achievement of EAS LDL-C targets at least once during
treatment, n (%)
Timeframe Target
< 100 mg/dL
(< 2.5 mmol/L)
< 70 mg/dL
(< 1.8 mmol/L)
Weeks 0–26a (n = 29) 15 (51%) 8 (28%)
Weeks 0–78a (N = 23) 16 (70%) 9 (39%)
Weeks 0–126b (n = 19 12 (53%) 8 (42%)
Weeks 0–256b (n = 19) 14 (74%) 11 (58%)
EAS European Atherosclerosis Society, LDL-C Low-density
lipoprotein cholesterol
aPhase 3 study
bPhase 3 and extension study; values represent number of patients and
percentage of enrolled population achieving LDL-C targets at least once in
the timeframe
Table 3 Rates for MACE from recent data sources in HoFH
HoFH background [8] Mipomersen-treated HoFH [8] Lomitapide-treated [7] Evolocumab treated [9]
Number of patients 23 23 19 106
Mean age at baseline 31 years 30.7 years 34 years
Mean baseline LDL-C 455 mg/dL 336 mg/dL 324 mg/dL
Mean LDL-C between 6 and
12 months on treatmenta
NA 331 mg/dL 166 mg/dL 286 mg/dL
Apheresis NR None 62% 32%
CVD at baseline NR NR 93% 51%
Number of major CV eventsb 12 4 2 4
Number of patient years 46 35 98 185
Annualized event rate 26.1% 11.4% 2.0% 2.1%
Events/1000 months 21.7 9.5 1.7 1.8
LDL-C low-density lipoprotein cholesterol, NA not applicable, NR not reported [7–9]
aRange of follow-up based on data availability: 1-year data for mipomersen, 26-week data for lomitapide, 48-week data for evolocumab, calculated from %
reduction reported; CVD, cardiovascular disease [7–9]
bMACE was defined as CV death, non-fatal myocardial infarction (MI), unstable angina pectoris and/or ischemic stroke, the evolocumab publication did not include
a MACE definition; however, it is believed to be defined as death (CV or non CV), MI, UA, and coronary revascularisation as this is the definition used in the CHMP
assessment report for evolocumab [10]
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many of these patients to reach EAS recommended
LDL-C target levels for the first time.
Most of the patients who achieved LDL-C targets did
so in the first 6 months of treatment. Assessment of
continuous maintenance of these LDL-C target levels is
difficult in a setting where background lipid-lowering
therapies, including apheresis, could be titrated upon
achievement of target levels. Similarly, not all patients
who achieve target during lomitapide dose titration are
likely to continue on the maximum dose reached in the
long-term. In our analysis, patients that reached the
100 mg/dL goal at least once, remained at goal for a me-
dian of 6 study visits suggesting that many of the pa-
tients receiving lomitapide are able to maintain the
target long-term. Nevertheless, the data provided here
are a reflection of the potential to reach target, rather
than an indication of maintenance of LDL-C at target.
The annualized MACE rates in HoFH patients treated
with mipomersen, lomitapide and evolocumab were
11.4, 2.0 and 2.1%, respectively. The pre-mipomersen ex-
posure annualized event rate in the mipomersen trial
was 26.1%.
We chose the dataset from the publication of Duell, et
al. [9] as a comparator as it reports relatively recent out-
come data for HoFH patients receiving standard of care
therapy before newer agents such as lomitapide, mipo-
mersen and evolocumab became available. We were un-
able to locate other recent data that would have allowed
us to calculate annualized event rates for HoFH patients
receiving conventional lipid-lowering therapy.
One of the major limitations of our MACE rate com-
parison is that the lomitapide studies were open-label
and did not include a control group receiving placebo.
Similarly, neither the mipomersen nor the evolocumab
studies include placebo arms of sufficient duration to as-
sess CV event rates. The background event rate for pa-
tients receiving conventional lipid lowering therapy used
for this comparison is therefore derived from the
pre-treatment mipomersen cohort that differs in import-
ant aspects, such as apheresis usage, baseline LDL-C
levels, or CVD rates at baseline from the population en-
rolled in the lomitapide and evolocumab studies. Indeed,
the patients in the Duell study had baseline LDL-C
values of 455 mg/dL, which is significantly higher than
the 336 mg/dL and 324 mg/dL in the lomitapide and
evolocumab studies. This may be due to underlying dis-
ease severity or due to less intensive background ther-
apy, specifically apheresis (63 and 32% of patients in the
lomitapide and evolocumab trials received apheresis at
baseline, compared with none in the mipomersen stud-
ies). However, baseline LDL-C levels are likely a strong
predictor of achievable LDL-C reductions and CV risk
and are therefore a significant confounding factor in our
analysis. Baseline CVD prevalence is another important
potential confounder. In the lomitapide studies baseline
CVD prevalence was 93%, it was 51% in the evolocumab
study and not reported for mipomersen.
Further limitations of this post-hoc, retrospective ana-
lysis include small sample sizes, relatively short treat-
ment durations, and the possible biases inherent in
conducting retrospective evaluations of this type. Im-
portantly, the CV event rate reported by Duell et al. [9]
could be skewed by subjects experiencing recurrent
events (7 patients account for 12 events) or preferential
recruitment of subjects with above average cardiovascu-
lar risk. Our study also relied on AE reporting for cap-
ture of MACE and events were not formally adjudicated.
It is therefore possible that we may not have captured all
events, or that some events, such as unstable angina,
may have been misclassified. Furthermore, not all pa-
tients enrolled in the pivotal trial entered the lomitapide
extension study, thereby introducing potential bias in
the extension trial population towards a healthier ‘sur-
vivor’ population. The mipomersen treatment duration
was also significantly shorter than the lomitapide expos-
ure, and it is conceivable that longer treatment with
mipomersen may have been associated with a progres-
sive lowering of MACE rates. Thus, our findings cannot
be regarded as a definitive estimation of MACE reduc-
tion with lomitapide, and can also not be used to draw
any definitive conclusions about the long-term outcome
associated with any one of the novel lipid-lowering ther-
apies. It would have been preferable to combine data
from multiple HoFH cohorts to obtain averaged CV
event rates in patients receiving conventional
lipid-lowering therapy, but we were not able to locate
any data that would have allowed us to calculate annual-
ized CV event rates.
Despite major limitations our data, along with the data
for mipomersen and evolocumab, suggest that CV risk
in HoFH can be reduced by pharmacotherapies that re-
duce LDL-C. The cohort of patients with the highest
LDL-C (pre-mipomersen; LDL-C 455 mg/dL) had the
highest event rates. Reducing the LDL-C in this cohort
to levels comparable to those found at baseline in the
lomitapide and evolocumab studies was associated with
an approximate 50% reduction in MACE. The event
rate, however, remained higher than that seen with lomi-
tapide and evolocumab, likely because of prior and on-
going increased exposure of the vasculature to LDL.
Baseline LDL-C levels were comparable for lomitapide
and evolocumab (336 mg/dL and 324 mg/dl) and
on-treatment MACE rates were remarkably similar. Al-
though lomitapide lowered LDL-C more than evolocu-
mab, differences in the prevalence of CVD at baseline
(93% for lomitapide versus 51% for evolocumab) may
have influenced CV event rates. The prognostic import-
ance of LDL-C is reinforced by data from Raal et al.,
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who showed that lowering LDL-C from 615 mg/dl to
452 mg/dL with conventional lipid-lowering therapy was
also associated with delayed cardiovascular events and
prolonged survival in patients with HoFH [10].
Conclusions
Lomitapide lowered LDL-C significantly in patients with
HoFH allowing many patients to reach EAS recom-
mended targets for the first time. Comparison of MACE
event rates among several HoFH cohorts show that car-
diovascular event rates correlate with LDL-C. Lomita-
pide and other novel lipid-lowering therapy may thus
improve the prognosis of patients with HoFH.
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